Health Canada has published its first prebiotic monograph, and if you manufacture or plan to bring a prebiotic natural health product to the Canadian market, this update changes the compliance picture in meaningful ways.
Released on April 24, 2026, by the Natural and Non-prescription Health Products Directorate (NNHPD), the document provides a standardized framework for Product Licence Applications (PLAs) covering prebiotic ingredients. For brands that have been waiting for regulatory clarity in this space, the wait is over.
Understanding what the prebiotic monograph covers and how to apply it correctly is critical before you move forward with a new submission or update an existing product. The requirements touch everything from permitted ingredients and dosage ranges to the exact health claims your label can carry.
Getting any of these elements wrong can delay your NPN approval or, worse, trigger a compliance issue after your product is already on market.
Which Prebiotic Ingredients Are Covered
The prebiotic monograph covers eight medicinal ingredients: Acacia (gum arabic), Fructooligosaccharides (FOS), Short-chain fructooligosaccharides (scFOS), Inulin, Transgalactooligosaccharides (GOS), Xylooligosaccharides (XOS), 2′-Fucosyllactose, and Lacto-N-neotetraose. Each ingredient is defined with proper names, common names, and source information, including the specific plant species and plant parts recognized by Health Canada.
This is not a catch-all for any ingredient a brand might position as a prebiotic. If your ingredient is not on this list, the monograph does not apply, and you will need to submit supporting evidence through a Class III application pathway.
Knowing which category your product falls into before you start building your submission is the kind of foundational step that saves significant time downstream.
Prebiotic Claims vs. Fibre Claims: An Important Distinction
One of the most practically important points in Health Canada’s prebiotic monograph is the firm separation between prebiotic claims and fibre-content claims. The two are assessed independently, and the monograph is explicit: a fibre-content claim must not imply a prebiotic effect, and a prebiotic claim must not imply a fibre benefit.
This matters because some of the listed ingredients, such as Inulin and Acacia, are eligible for both types of claims. However, Health Canada recommends keeping these claims separate on the label to avoid any misinterpretation. If your product qualifies for both, the language and placement on your label need to reflect that distinction clearly. Overlooking this detail during label development is a common mistake that can hold up a submission or prompt a label amendment request.
Dosage Ranges and Health Claims That Apply
The monograph organizes permitted claims into three tables. The first covers prebiotic and bacterial growth claims, the second covers fibre and digestive health claims, and the third addresses constipation and irregularity relief. Each claim type is tied to specific ingredients and daily dose ranges.
For example, Inulin sourced from chicory root or Jerusalem artichoke supports a prebiotic claim at 5 to 15 grams per day, while Acacia requires 10 to 20 grams per day for the same claim. XOS supports a prebiotic and digestive health claim at just 1.4 to 8 grams per day, which is notably lower than other ingredients. For constipation relief, only Inulin and FOS or scFOS are permitted, and at higher minimum doses.
If your formulation includes more than one prebiotic ingredient from the monograph, combination rules apply. The combined daily total must not exceed 15 grams, and XOS specifically must not exceed 8 grams per day regardless of the combination. Understanding how these rules interact with your formula is not optional; it directly affects what you can and cannot claim on your label.
Labelling and Directions for Use
The prebiotic regulations also specify mandatory directions for use that must appear on your label. Most products must instruct consumers to take the product with at least 250 mL of liquid and to maintain adequate fluid intake. Products in powder form carry an additional direction to mix the product in liquid immediately before consumption.
For products containing Inulin or FOS at 5 grams or more per day, your label must also include the following known adverse reaction statement: users may experience temporary gas and bloating. This is not optional language. Products containing Inulin and intended for constipation relief have additional caution and contraindication requirements, including instructions to consult a healthcare practitioner if symptoms persist, and a contraindication for users with fever or undiagnosed gastrointestinal conditions.
Duration of use restrictions also apply for certain ingredients. Acacia at doses above 10 grams per day requires a direction to seek practitioner guidance for use beyond 12 weeks. XOS at doses above 4 grams per day carries a 3-week limit before the same guidance applies. These are not suggestions; they are requirements that must appear on your label or you risk a non-compliant product.
Class II vs. Class III Applications and Combination Restrictions
Not every prebiotic formulation qualifies as a Class II application under this monograph. Certain ingredient combinations automatically require a Class III application with supporting evidence.
These restricted combinations include Inulin or FOS with invertase, GOS with lactase or alpha-galactosidase, XOS with hemicellulase or xylanase, 2′-Fucosyllactose or Lacto-N-neotetraose with lactase, and Acacia with any digestive enzymes.
If your product includes any of these pairings, planning for a Class III submission from the start will prevent a costly reclassification mid-process.
Key Takeaways
- Health Canada’s new prebiotic monograph covers eight specific medicinal ingredients, each with defined sources, dosage ranges, and permitted health claims.
- Prebiotic claims and fibre-content claims are legally distinct and must be kept separate on your product label.
- Combination rules limit total daily prebiotic doses to 15 grams and impose specific caps on XOS; certain ingredient pairings require a Class III application.
- Label requirements include mandatory directions for use, known adverse reactions for applicable products, and duration of use restrictions for Acacia and XOS.
- Products not covered by the monograph or falling outside Class II criteria will need evidence-based submissions through the Class III pathway.
Frequently Asked Questions
Does this monograph cover all prebiotic ingredients currently on the market?
No. The NNHPD prebiotic monograph covers eight specific ingredients. If your prebiotic ingredient is not among them, this monograph does not provide a licensing pathway for it, and you would need to pursue a Class III application with supporting clinical evidence. That said, for the ingredients it does cover, the monograph provides a clear and efficient route to market authorization.
Can I combine prebiotic and fibre claims on the same label?
Not without careful attention to how those claims are presented. Health Canada’s prebiotic regulations treat these as distinct concepts assessed independently. While eligible ingredients may qualify for both, the monograph specifically recommends keeping the two claim types separate on the label to avoid implying a connection between the effects. Working with a regulatory expert during label development can help you navigate this correctly.
Is it difficult to qualify for a prebiotic claim under this new framework?
It depends on your formula. For products using well-supported ingredients like Inulin, FOS, GOS, or XOS at the right dose ranges, the pathway is straightforward because the monograph is designed to streamline Class II applications. The complexity increases when combination products are involved or when claims cross into constipation relief territory, which carries additional requirements. With the right preparation, qualifying under this framework is entirely achievable.
What This Means for Your Business
Health Canada’s prebiotic monograph creates both opportunity and obligation. Brands that move quickly and correctly can get products to market with a clear regulatory pathway. Those who misread the dosage requirements, combine restricted ingredients without proper evidence, or use non-compliant label language will face delays, requests for additional information, or rejected applications.
Quality Smart Solutions has been guiding NHP brands through Health Canada’s regulatory framework for nearly two decades. Whether you are building a new prebiotic product from the ground up or reviewing an existing formulation against the new monograph requirements, our team can help you assess your product, structure your application, and prepare compliant labelling.
To learn more about how we support brands through the full licensing process, explore our NHP Licensing services or contact us to speak with one of our regulatory specialists.
